Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) following treatment for ovarian cancer

被引：0
|
作者：
Gupta, B. [1 ]
Sait, S. N. [1 ]
Block, A. W. [1 ]
Ford, L. A. [1 ]
Moysich, K. B. [1 ]
Baer, M. R. [1 ]
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
17506
引用
收藏
页数：1
相关论文
共 50 条
  • [31] IMMUNOHISTOCHEMICAL AND CYTOGENETIC CORRELATION WITH TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS)
    Chai, J.
    Nwaoduah, N.
    Shi, Y.
    Verma, A.
    Gong, J.
    Wang, Y.
    LEUKEMIA RESEARCH, 2021, 108 : S23 - S24
  • [32] Del 5q as a sole cytogenetic abnormality in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Washington, LT
    Glassman, A
    Ibrahim, S
    Lai, R
    LABORATORY INVESTIGATION, 2001, 81 (01) : 182A - 182A
  • [33] Identification of Dido1 Mutation Associated with Familial Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML)
    Galili, Naomi
    Trifonov, Vladimir
    Ewalt, Mark
    Mukherjee, Siddhartha
    Rabadan, Raul
    Raza, Azra
    BLOOD, 2012, 120 (21)
  • [34] Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) Associated with PARP Inhibitors: A Real-World Analysis
    Gajra, Ajeet
    Zettler, Marjorie E.
    Klink, Andrew J.
    Feinberg, Bruce
    BLOOD, 2020, 136
  • [35] Del 5q as a sole cytogenetic abnormality in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Washington, LT
    Glassman, A
    Ibrahim, S
    Lai, R
    MODERN PATHOLOGY, 2001, 14 (01) : 182A - 182A
  • [36] Rigosertib activity in patients with a myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) relapsed or refractory to hypomethylating agents
    Navada, S. C.
    Odchimar-Reissig, R.
    Reddy, E. P.
    Demakos, E. P.
    Holland, J. F.
    Wilhelm, F.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2013, 37 : S146 - S146
  • [37] Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment
    Alhajahjeh, Abdulrahman
    Stahl, Maximilian
    Kim, Tae K.
    Kewan, Tariq
    Stempel, Jessica M.
    Zeidan, Amer M.
    Bewersdorf, Jan Philipp
    EXPERT REVIEW OF ANTICANCER THERAPY, 2025,
  • [38] HEXAMETHYLENE BISACETAMIDE (HMBA) IN MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID-LEUKEMIA (AML)
    ANDREEFF, M
    STONE, R
    YOUNG, C
    TONG, W
    ERVIN, T
    TAFURI, A
    KOLITZ, J
    RIFKIND, R
    KUFE, D
    MARKS, P
    LEUKEMIA, 1991, 5 (02) : 174 - 174
  • [39] Maintenance treatment with 5-azacitidine for patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (MDS-AML) in complete remission (CR) after induction chemotherapy
    Groevdal, M.
    Kahn, R.
    Jansson, M.
    Aggerholm, A.
    Antunovic, P.
    Astermark, J.
    Bernell, P.
    Engstroem, L.
    Kjeldsen, L.
    Linder, O.
    Nilsson, L.
    Olsson, A.
    Skovholm, M.
    Tangen, J.
    LEUKEMIA RESEARCH, 2009, 33 : S49 - S50
  • [40] TRISOMY-14 IN ACUTE MYELOGENOUS LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS)
    TOZE, CL
    BARNETT, MJ
    NAIMAN, SC
    HORSMAN, DE
    BLOOD, 1994, 84 (10) : A626 - A626
12345